Combining Robot-Assisted Gait Training and Non-Invasive Brain Stimulation in Chronic Stroke Patients: A Systematic Review

Federica Bressi*, Alex Martino Cinnera2, Giovanni Morone2, Benedetta Campagnola1, Laura Cricenti1, Fabio Santacaterina1, Sandra Miccinilli1, Loredana Zollo3, Stefano Paolucci2, Vincenzo Di Lazzaro4, Silvia Sterzi1 and Marco Bravi1

1 Physical Medicine and Rehabilitation Unit, Campus Bio-Medico University of Rome, Rome, Italy, 2 Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Santa Lucia Foundation, Rome, Italy, 3 Unit of Advanced Robotics and Human-Centred Technologies, Campus Bio-Medico University of Rome, Rome, Italy, 4 Unity of Neurology, Neurophysiology, Neurobiology, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy

Gait impairment is one of the most common disorders of patients with chronic stroke, which hugely affects the ability to carry out the activities of daily living and the quality of life. Recently, traditional rehabilitation techniques have been associated with non-invasive brain stimulation (NIBS) techniques, which enhance brain plasticity, with the aim of promoting recovery in patients with chronic stroke. NIBS effectiveness in improving gait parameters in patients with chronic stroke has been in several studies evaluated. Robotic devices are emerging as promising tools for the treatment of stroke-related disabilities by performing repetitive, intensive, and task-specific treatments and have been proved to be effective for the enhancement of motor recovery in patients with chronic stroke. To date, several studies have examined the combination of NIBS with robotic-assisted gait training, but the effectiveness of this approach is not yet well established. The main purpose of this systematic review is to clarify whether the combination of NIBS and robot-assisted gait training may improve walking function in patients with chronic stroke. Our systematic review was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Studies eligible for review were identified through PubMed/MEDLINE, Embase, Scopus, and PEDro from inception to March 15, 2021, and the outcomes considered were gait assessments. Seven studies were included in the qualitative analysis of this systematic review, with a total population of 186 patients with chronic stroke. All studies specified technical characteristics of robotic devices and NIBS used, with high heterogeneity of protocols. Methodological studies have shown a significantly greater improvement in walking capacity recorded with 6MWT. Finally, research studies have highlighted a positive effect on walking recovery by combination of robot-assisted gait training with non-invasive brain stimulation. Furthermore, future studies should identify the best characteristics of the combined therapeutic protocols.

Systematic Review Registration: CRD42021244869.

Keywords: robotics, transcranial direct current stimulation, chronic stroke, robot-assisted, exoskeleton, transcranial magnetic stimulation, TMS, NIBS
INTRODUCTION

Stroke is the leading cause of disability worldwide. In Europe, in 2017, there were 1.12 million strokes (1). In the United States, more than 795,000 have a stroke each year, and about 610,000 of these are first strokes (2). Motor impairment is the most common consequence of stroke, which can be regarded as loss or limitation of function in muscle control or movement in an arm and a leg on one side of the body (3). Motor impairment of the lower limb, frequently present among patients with stroke, often results in gait disorders, hugely impacting the ability to carry out the activities of daily living and the quality of life (4, 5). Despite the efficacy of a large variety of physiotherapy interventions in improving functional outcomes in all post-stroke phases (6, 7), 6 months after stroke, more than 30% of survivors cannot walk independently (3). For this reason, it is necessary to develop novel neurorehabilitation treatments to minimize long-term disability (8).

Based on this, in recent decades, new technologies have been introduced and coupled with physical therapy with the aim of enhancing motor recovery of the lower limbs and walking ability. Among these, the use of robotic devices is emerging as promising tools for the treatment of stroke-related disabilities; robotic devices allow repetitive, intensive, and task-specific treatments that have been proved to be effective for promoting motor recovery in patients with chronic stroke (9). Robotics devices for walking rehabilitation can be classified according to the way they assist a patient’s lower limbs. Morone et al. (10) distinguished two groups of these devices: exoskeletons that move the hip, knee, and ankle joints during the gait phases, and end-effector robots that move only the feet, often positioned on a support that imposes a specific trajectory, simulating the stance and swing phases during gait training.

A recent meta-analysis has shown that people who receive electromechanical-assisted gait training in combination with physiotherapy after stroke are more likely to achieve independent walking than people who receive gait training without these devices (11). Moreover, several studies have shown that robotic-assisted gait training (RAGT) led to functional improvement even in the chronic phase of stroke (12, 13). Parallelly, the potential of rehabilitation techniques has been enhanced by the use of non-invasive brain stimulation (NIBS), which facilitates neuroplasticity. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are the two most common types of NIBS, which, by modulating cortical excitability, may induce plastic changes in the brain (14). tDCS and TMS techniques seem to be effective in enhancing motor performance in patients with stroke (15–17). NIBS effectiveness in improving gait parameters has been proved by several randomized controlled trials on patients with chronic stroke (18, 19). Although tDCS in association with neurorobotics was suggested as feasible, the efficacy is currently under debate (20).

In this regard, NIBS and neurorobotics training or functional task training (21) have been combined with the aim of maximizing the enhancement of cortical plasticity. Therefore, RAGT will help improve the walking ability of patients with chronic stroke. Optimization of training protocol, promoting active participation of patients, and the use of add-on techniques, such as tDCS (22), may be considered to enhance the effects of RAGT in patients with chronic stroke. However, to date, the efficacy of NIBS, combined with robotic-assisted gait training, has not been well established. Therefore, the main purpose of this systematic review is to clarify whether the combination of NIBS and robot-assisted gait training may improve walking function in patients with chronic stroke.

MATERIALS AND METHODS

The systematic review was conducted in three steps in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (23). 1. literature search; 2. data extraction, and 3. critical appraisal. The review protocol has been registered on PROSPERO (registration ID: CRD42021244869) (International Prospective Register of Systematic Reviews).

Literature Search

An online systematic search was performed using the most popular electronic databases: PubMed/MEDLINE, Embase, Scopus, Web of Science (WOS), Ebsco, and PEDro from inception to March 15, 2021. We used the combination of medical subject heading (MeSH) terms and free-text terms and were adjusted according to specification of each database. The search strategy is shown in Appendix 1 in Supplementary Material. The language of publication was limited to English. We selected all design studies that use NIBS coupled with RAGT. Three reviewers (B.C., L.C., and M.B.) independently and synchronously screened the titles and abstracts to identify potentially eligible articles. In case an article was only selected by one reviewer, the three reviewers discussed whether to include a study in the full-text analysis. A fourth reviewer (A.M.C.) was consulted in case a consensus between the first three reviewers was not reached. Subsequently, all the reviewers independently assessed the full text of the selected articles. After the selection of eligible studies, data were extracted, included the first author’s full-name, year of publication, type of study, number of intervention and the control group, characteristics of population (e.g., mean age, prevalence of male), characteristics of stroke, type of exoskeleton and NIBS used, duration and follow-up, and outcomes used.

Data Extraction

In agreement with the PRISMA guidelines (23), we reported the results using the PICOST-DS tool, focusing on the participant, intervention, comparator, outcomes, time, setting, study design (24). The PICOST-DS model was adopted to conduct an evidence-based practice literature search and, consequently, to enhance the quality of health education interventions and programs (25) (Table 1).

Critical Appraisal

The methodological quality was assessed using the version two of the Cochrane risk-of-bias tool for randomized trials (RoB 2) (26) to evaluate the quality of randomized controlled trials (RCTs).
Instead, we used methodological index for non-randomized studies (MINORS) (27) to examine non-RCTs studies. The RoB 2 is structured into a fixed set of domains of bias, focusing on different aspects of trial design, conduct, and reporting. Within each domain, a series of questions (“signaling questions”) aim to elicit information about features of the trial that is relevant to risk of bias. A proposed judgment about the risk of bias arising from each domain is generated by an algorithm based on answers to the signaling questions. Judgment can be “low” or “high” risk of bias, or can express “some concerns” (26). The MINORS index includes 12 items that are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate), the global ideal score being 16 for non-comparative studies and 24 for comparative studies.

RESULTS
Data Synthesis
A flow diagram of the research is reported in Figure 1. We found 319 records through the research method. After screening of the title and abstract, 303 articles were excluded because they did not meet our inclusion criteria (Table 1). Therefore, 17 articles were assessed for eligibility. After full-text reading, 7 studies were included in the qualitative analysis of this systematic review (20, 22, 28–32). The characteristics of the included studies are summarized in Table 2. It was revealed that studies were published between 2011 (22) and 2020 (28). Except for one retrospective clinical study (28), all the included studies were RCTs, and four of these studies were designed as pilot RCT (22, 29, 30, 32) and one as feasibility RCT (20).

Population
The studies included a total population of 186 patients with chronic stroke (72 females) aged ≥ 18 years. The sample size of the studies ranged from 8 (20) to 40 (31), and mean patients’ age in the studies ranged from 61 (29) to 72 (28) years. According to the inclusion criteria, time from the stroke onset is ≥ 6 months for all selected study: mean time between the stroke onset and the

---

TABLE 1 | The PICOTS-SD model.

| P-Participants | Adult (> 18 years) |
|---------------|--------------------|
| Affected with chronic (> 6 months) stroke |
| I-Intervention | EXOSKELETON associated with Non Invasive Brain Stimulation (NIBS) |
| C-Comparator | Presence of a control group with characteristics comparable to the experimental group |
| O-Outcomes | Focus on mobility index |
| T-Time | No limits of time were imposed |
| S-Setting | Rehabilitation both inpatients and outpatients |
| SD-Study design | All design studies |

PICOTS-SD = participant, intervention, comparator, outcomes, time, setting, study design.

---

![Flow Diagram](Image)
| Author          | Study design            | Group 1                                                                 | Group 2                                                                 | Group 3                                                                 | Additional Therapy                                                                 | Outcome       | Follow-up             | Drop out |
|----------------|-------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------|-----------------------|----------|
| Danzl et al.   | Feasibility of an RCT   | Lokomat (Hocoma Inc, Zurich, Switzerland) tDCS 3 days/week for 4 weeks (20–40 mins) | Lokomat (Hocoma Inc, Zurich, Switzerland) Sham tDCS 3 days/week for 4 weeks (20–40 mins) | -                                                                      | 10MWT; BBS, FAC, SIS-16, TUG, qualitative data                                      | After treatment | 1 month after treatment | 2 during follow-up evaluation |
| Geron et al.   | Pilot RCT               | Gait Trainer GT1 (Reha-Stim, Berlin, Germany) tDCS 5 days/week for 2 weeks (50 mins) | Gait Trainer GT1 (Reha-Stim, Berlin, Germany) Sham tDCS 5 days/week for 2 weeks (50 mins) | -                                                                      | 30 mins of LL muscle strengthening and JM                                           | After treatment | 1 month after treatment | -        |
| Naro et al.    | Retrospective clinical study | Lokomat®Pro (Hocoma Inc, Zurich, Switzerland) bi-hemispheric tDCS 6 days/week for 8 weeks (60 mins) | Lokomat®Pro (Hocoma Inc, Zurich, Switzerland) Sham tDCS 6 days/week for 8 weeks (60 mins) | Lokomat®Pro (Hocoma Inc, Zurich, Switzerland) bi-hemispheric tDCS 6 days/week for 8 weeks (60 mins) | physical rehabilitation program (1 h) daily                                       | 6MWT, 10MWT, FAC, FM, MI, MEP, Tinetti Scale                                   | After treatment | 1 month and 3 months after treatment | 2: 1 during follow-up evaluation |
| Picelli et al. | Pilot RCT               | G-EO System Evolution (Reha Technology, Olten, Switzerland) Anodal tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Sham tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Anodal tDCS 5 days/week for 2 weeks (20 mins) | -                                                                     | 6MWT, FAC, MAS, MI leg scores, R-MI, ST gait parameters | After treatment | 2 weeks and 4 weeks after treatment | -        |
| Picelli et al. | Pilot RCT               | G-EO System Evolution (Reha Technology, Olten, Switzerland) Cathodal tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Anodal tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Cathodal tDCS 5 days/week for 2 weeks (20 mins) | -                                                                     | 6MWT, AS, FAC, MI leg scores, ST gait parameters                                   | After treatment | 2 weeks and 4 weeks after treatment | -        |
| Picelli et al. | RCT                     | G-EO System Evolution (Reha Technology, Olten, Switzerland) Cathodal tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Anodal tDCS 5 days/week for 2 weeks (20 mins) | G-EO System Evolution (Reha Technology, Olten, Switzerland) Cathodal tDCS 5 days/week for 2 weeks (20 mins) | -                                                                     | 6MWT, AS, FAC, MI ST gait parameters                                              | After treatment | 2 weeks and 4 weeks after treatment | 1 during follow-up evaluation |
| Seo et al.     | Pilot RCT               | Walkbot_S (Walkbot_S; PAS Mechanics, Seoul, Republic of Korea) tDCS 5 days/week for 2 weeks (45 mins) | Walkbot_S (Walkbot_S; PAS Mechanics, Seoul, Republic of Korea) Sham tDCS 5 days/week for 2 weeks (45 mins) | -                                                                      | 6MWT, 10MWT, BBS, FAC, FM-LE, MRC                                               | After treatment | 4 weeks after treatment | 4 during follow-up evaluation |

6MWT: 6 min walking test; 10MWT: 10-meter walking test; AS: Ashworth scale; BBS: Berg balance scale; CL: contralesional; FAC: functional ambulatory category; FM: functional independence measure; FMA-LE: Fugl-Meyer assessment of lower extremity; IL: ipsilesional; JM: joint mobilization; LL: lower limb; MAS: modified Ashworth scale; MEP: motor-evoked potentials; MI leg subscore, Motricity index leg subscore; MRC: medical research council scale; RCT: randomized control trial; R-MI: rivermead motricity index; SIS-16: stroke impact scale 16; ST: spatiotemporal; tDCS: transcranial direct current stimulation; tsDCS: transspinal direct current stimulation; TUG: timed up and go.
start of treatment ranged between 10 (28) and 152.5 months (30) (see Table 3).

Intervention
The approach used in the intervention group was combined robot-assisted gait training and NIBS stimulation, with the latter performed before training (20, 28, 30), during training (22, 28, 29, 31, 32), or after training (28) (complete treatment characteristics are reported in Table 2).

Robotic Treatment Characteristics
All studies specified technical characteristics of robot devices (i.e., the model, the manufacturing company, and the country of production): G-EO System Evolution (Reha Technology, Olten, Switzerland) was the only one used in more than one study (29, 31, 32). Other robotic devices utilized were Gait Trainer GT1 (Reha-Stim, Berlin, Germany) (22); Lokomat (Hocoma Inc., Zurich, Switzerland) (20); Lokomat@Pro (Hocoma Inc., Zurich, Switzerland) (26), and Walkbot_S (P&S Mechanics, Seoul, Republic of Korea) (30). Intervention frequency ranged from 3 times a week (20) to 6 times a week (28), with a mean duration session of 33 min (minimum of 20 min; maximum of 60 min); however, more than half of the training programs was carried out 5 times a week for 2 weeks, and every session lasted 20 min (22, 29, 31, 32). Two studies added a traditional therapy to the robotic one; Geroin et al. (22) associated lower limbs muscle strengthening and joint mobilization exercises with exoskeleton therapy, and Naro et al. (28) added 1 h of a physical rehabilitation program. Conventional therapy and exoskeleton therapy with sham NIBS were mostly provided for the control group. One study (30) was sponsored by the manufacturer of the gait robot. For other studies, it was either explicitly declared that the work was not supported by any grant from the public or private sector or that there was nothing to disclose financially (20, 22, 28), or information funding was not available (29, 31, 32).

NIBS Characteristics
All studies included in the systematic review used tDCS treatment, however, with high heterogeneity of protocols. All the studies set the intensity of stimulation at 2 mA with the exception of one using 1.5 mA (22). The electrode positioning area was specified for each study, following the 10–20 international EEG system (33). The cortical motor area was the most used site of stimulation, with exception of two studies (31, 32), in which the position of the electrodes varied according to the study group analyzed. Regarding electrodes, five studies (20, 22, 28–30) used a rectangular electrode, while the remaining two studies (31, 32) used circular electrodes. In addition, the Cathodal and Anodal electrodes had the same size—only Danzl et al. (20) – used an anodal electrode smaller than the cathodal one (25 vs. 35 cm²). The duration of stimulation ranged from 7 to 20 min, five out seven studies used 20 min of stimulation, while Geroin et al. (22) used 7 min of stimulation, and Naro et al. (28) used 10 min of stimulation. The technical data of the stimulator (i.e., name, the manufacturing company, and the country of production) were available for all the studies other than Danzl et al. (20) and Naro et al. (28) (complete NIBS characteristics are available in Table 4).

Comparison
In the studies selected for the current systematic review, only three studies used a RCT sham controlled study design (20, 22, 30). Three studies are methodological studies, in which randomization was used to test different stimulation sites (i.e., cerebellum or spinal cord) or different types of stimulation (anodal and cathodal) (29, 31, 32). In the last study (28), a comparison was performed between the effects of NIBS delivered before, during, or after RAGT.

Outcome
In two out three studies that compared real stimulation (anodal on M1) and sham stimulation (supraorbital stimulation), a significant clinical improvement was found in the real group with respect to the sham group. Danzl et al. (20) found a statistical difference (time x group interaction) in the FAC, TUG, and SIS-16 score evaluated before and immediately after training. Seo et al. (30) found a statistical improvement in the real group in the FAC and 6MWT score at a 4-week follow-up. Geroin et al. (22) reported only a TIME effect between the two groups without time x group interaction (real vs. sham) (Table 2).

Methodological studies have shown a significantly greater improvement in a walking capacity recorded with 6MWT. Picelli et al. (29) find a statistical improvement in groups that underwent anodal tDCS + cathodal spinal stimulation (tsDCS) during RAGT with respect to anodal tDCS or cathodal tsDCS alone. In Picelli et al. (32), a significant improvement was found in the group undergoing a cathodal cerebellar stimulation plus cathodal tsDCS with respect to the patients that underwent anodal tDCS plus cathodal tsDCS. Differently, no difference has been reported by two different protocols of cerebellar transcranial direct current stimulation combined with transcutaneous spinal direct current stimulation on RAGT (31) and in the comparison of dual-site direct current stimulation (dstDCS) performed before, during, and after RAGT (28).

All the studies performed the clinical evaluation before, after treatment, and in the post-intervention follow-up. Time between the end of the treatment and the follow-up ranged between 2 weeks (29, 31, 32) and 3 months (28). More than half of the included studies (28, 29, 31, 32) had outcome measurements at multiple time points, up to 3 months after the intervention. All the studies used the functional ambulatory category (FAC), of which two used it as primary outcome measure (28, 30). The 6-meter walking test (6MWT) was assessed in 5 out of seven studies (22, 28, 29, 31, 32) as a primary outcome, while Seo et al. (30) used it as a secondary outcome. More than a half of the studies (22, 29, 31, 32) analyzed spatiotemporal gait parameters as a secondary outcome. Other scales that were frequently used were Motricity Index leg-subscore (22, 28, 29, 31, 32), 10-meter walking test (10MWT) (18, 20, 26, 28), and Ashworth scale (29, 31, 32). Outcomes that were less considered were Berg Balance Scale (BBS), Fugl-Meyer Assessment of Lower Extremity (FMA-LE), Medical Research Council (MRC) Scale, Modified Ashworth Scale (MAS), Rivermead Mobility Index, Stroke Impact Scale 16 (SIS-16), Timed Up and Go (TUG), Functional Independence Measure (FIM), and Tinetti Scale. Additionally, Naro et al. (28) investigated the ratio between the motor-evoked potential
### TABLE 3 | Characteristics of the participants.  

| Study | Group 1 | Group 2 | Group 3 |
|-------|---------|---------|---------|
| | Characteristics of participants | Characteristics of stroke | Characteristics of participants | Characteristics of stroke |
| | | | | |
| Naro et al. (28) | 9 (5:4) 68 ± 4 Chronic stroke (9:0) | 15 (9:6) 66 ± 5 Chronic stroke (15:0) | 13 (8:5) 72 ± 4 Chronic stroke (13:0) |
| | Month after stroke: 10 ± 2 | Month after stroke: 11 ± 3 | Month after stroke: 8 ± 2 |
| | Affected hemisphere (11:4) | Affected hemisphere (11:4) | Affected hemisphere (10:3) |
| | Lesion localization: cortical 33%; large subcortical 11%; cortical-subcortical 44%; lacunar 11% | Lesion localization: cortical 40%; large subcortical 13%; cortical-subcortical 40%; lacunar 7% | Lesion localization: cortical 31%; large subcortical 15%; cortical-subcortical 38%; lacunar 15% |
| Picelli et al. (29) | 10 (3:7) 64.8 ± 6.0 Chronic stroke (10:0) | 10 (2:8) 61.0 ± 7.2 Chronic stroke (10:0) | 10 (3:7) 62.8 ± 11.8 Chronic stroke (10:0) |
| | Month after stroke: 61.3 ± 29.3 | Month after stroke: 54.8 ± 32.9 | Month after stroke: 51.9 ± 41.1 |
| | Affected hemisphere: N/A | Affected hemisphere: N/A | Affected hemisphere: N/A |
| | Lesion localization: cortical 40%; subcortical 30%; mixed 30% | Lesion localization: cortical 40%; subcortical 30%; mixed 40% | Lesion localization: cortical 30%; subcortical 30%; mixed 40% |
| Picelli et al. (31) | 20 (10:10) 63.9 ± 10.6 Chronic stroke (20:0) | 20 (9:11) 65.6 ± 9.7 Chronic stroke (20:0) | – – |
| | Month after stroke: 66.4 ± 48.8 | Month after stroke: 61.7 ± 40.1 | – – |
| | Affected hemisphere: N/A | Affected hemisphere: N/A | – – |
| | Lesion localization: cortical 30%; subcortical 40%; mixed 30% | Lesion localization: cortical 40%; subcortical 30%; mixed 30% | Lesion localization: cortical 30%; subcortical 30%; mixed 40% |
| Seo et al. (31) | 10 (3:7) 62.9 ± 8.9 Chronic stroke (8:2) | 11 (2:9) 61.1 ± 8.9 Chronic stroke (5:6) | – – |
| | Month after stroke: 152.5 ± 122.8 | Month after stroke: 75.5 ± 83.4 | – – |
| | Affected hemisphere (2:8) | Affected hemisphere (5:6) | – – |
| | Lesion localization: N/A | Lesion localization: N/A | – – |

F, female; H, Hemorrhagic stroke; I, ischemic stroke; L, left; M, male; R, right.
| Study                      | Stimulator Model (industry, country of production) | Anodal electrode Position; Size (cm²) | Cathodal electrode Position; Size (cm²) | Intensity | Duration (min) | Intervention in groups                                                                 |
|---------------------------|---------------------------------------------------|---------------------------------------|----------------------------------------|-----------|----------------|----------------------------------------------------------------------------------------|
| Danzl et al. (20)         | Not specified                                     | CMA controlling leg; 25 cm²           | Supraorbitally 35 cm²                  | 2 mA      | 20 min Before training                      | Group 1: anodal+cathodal tDCS  
Group 2: sham anodal+sham cathodal tDCS                                           |
| Geroin et al. (22)        | Phyaction 787 (Uniphy, The Netherlands)           | Affected CMA presumed controlling leg 35 cm² | Controlesional orbit 35 cm²           | 1.5 mA    | 7 min During training                        | Group 1: anodal+cathodal tDCS  
Group 2: sham anodal+sham cathodal tDCS  
Group 3: no NIBS                                                                  |
| Naro et al. (28)          | Not specified                                     | Affected M1 (C3 or C4 position) 35 cm² | Unaffected M1 (C3 or C4 position) 35 cm² | 2 mA      | 10 min  
Group 1: during training  
Group 2: after training  
Group 3: before training  | Group 1: anodal+cathodal tDCS  
Group 2: sham anodal+cathodal tDCS  
Group 3: no NIBS                                                                  |
| Pecelli et al. (29)       | Phyaction 787 (Uniphy, The Netherlands)           | Affected M1 (C3 or C4 position) 35 cm² | Unaffected orbit 35 cm²               | 2 mA      | 20 min During training                        | Group 1: anodal tDCS+sham tsDCS  
Group 2: sham tDCS+cathodal tsDCS  
Group 3: anodal tDCS+cathodal tsDCS                                                |
| Pecelli et al. (29)       | Starstim® (Neuroelectrics, Spain)                 | tDCS: Controlesional buccinator muscle 12.56 cm²  
tDCS: Lesioned M1, Cz position 12.56 cm²  
tDCS: shoulder of the unaffected hemibody 23.75 cm² | tDCS: Controlesional cerebellar hemisphere (O1 or O2 position) 12.56 cm²  
tDCS: Ipsilesional orbit 12.56 cm²  
tDCS: D10 spinous process 23.75 cm² | tcDCS: 2 mA  
tDCS: 2 mA  
tDCS: 2.5 mA | 20 min During training                        | Group 1: cathodal tDCS+cathodal tsDCS  
Group 2: anodal tDCS+cathodal tsDCS  
Group 3: anodal tDCS+cathodal tsDCS                                                 |
| Pecelli et al. (31)       | Starstim® (Neuroelectrics, Spain)                 | tDCS: buccinator muscle 12.56 cm²  
tDCS: shoulder of the unaffected hemibody 23.75 cm² | tDCS: cerebellar hemisphere (O1 or O2 position) 12.56 cm²  
tDCS: D10 spinous process 23.75 cm² | tcDCS: 2 mA  
tDCS: 2 mA  
tDCS: 2.5 mA | 20 min During training                        | Group 1: contralesional cathodal tDCS+cathodal tsDCS  
Group 2: ipsilesional cathodal tDCS+cathodal tsDCS  
Group 3: no NIBS                                                                  |
| Seo et al. (30)           | DC-Stimulator Plus (NeuroConn GmbH, Germany)      | CMA presumed controlling leg (lateral Cz position) 35 cm² | Forehead above the contralateral orbit 35 cm² | 2 mA      | 20 min Before training                         | Group 1: anodal tDCS  
Group 2: sham tDCS                                                                  |

CMA, cortical motor area.
### Results of the studies.

| Study | Primary outcomes | Secondary outcomes |
|-------|------------------|--------------------|
| Danz et al. (23) | **10MWT**: no significant differences between the groups at T1–T0 ($p = 0.19$) | **TUG**: significant improvement in the active tDCS group compared to the sham group ($p = 0.066$) |
| Naro et al. (25) | **6MWT**: significant improvement in group 1 and 2 compared to group 3 at T1 and T2. No significant difference between group 1 and 2 **10MWT**: significant improvement in group 1 and 2 compared to group 3 at T1 and T2. No significant difference between group 1 and 2 | **BBS**: no significant improvement in the active tDCS group compared to the sham group ($p = 0.919$) |
| Picelli et al. (29) | **6MWT**: no significant changes **10MWT**: significant difference between the treatments over time ($p < 0.001$) in relation to on-RAGT and post-RAGT **FIM**: improvement obtained over time was similar for all groups ($p < 0.001$) **Tinetti Scale**: significant difference between the treatments over time ($p < 0.001$) in relation to on-RAGT and post-RAGT **MI**: improvement obtained over time was similar for all groups ($p < 0.001$) **FAC**: significant difference between the treatments over time ($p < 0.001$) in relation to on-RAGT and post-RAGT | **SIS-16**: significant improvement in the active tDCS group compared to the sham group ($p = 0.062$) **Spatiotemporal gait parameters**: no significant differences between group 1 and 2, in both T1 and T2 evaluations. **6MWT**: significant differences in walking distance between the groups at T1–T0 ($p = 0.005$) evaluations. No significant difference between the groups at T1–T0 ($p = 0.650$) **10MWT**: no significant improvement in group 1 and 2 compared to group 3 at T1 and T2 evaluations. No significant difference between group 1 and 2 | **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.126$), T2–T0 ($p = 0.368$) and T3–T0 ($p = 0.342$) evaluations. **MI**: no significant difference between the groups at T1–T0 ($p = 0.107$), T2–T0 ($p = 0.385$) and T3–T0 ($p = 0.715$) evaluations. **AS**: no significant difference between the groups at T1–T0 ($p = 0.003$) and T2–T0 ($p = 0.016$) evaluations but not at the T3–T0 evaluation ($p = 0.405$). Significant difference in group 3 vs. group 1 results at T1–T0 ($p = 0.002$) and T2–T0 ($p = 0.013$) evaluations, as well as in group 3 vs. group 2 at T1–T0 ($p = 0.010$) and T2–T0 ($p = 0.015$) evaluations. No significant difference in group 2 vs. group 1 results. **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.512$), T2–T0 ($p = 0.416$), and T3–T0 ($p = 0.220$) evaluations |
| Picelli et al. (29) | **6MWT**: significant differences in walking distance between the groups at T1–T0 ($p = 0.041$). No significant difference between the groups at T2–T0 ($p = 0.650$) and T3–T0 ($p = 0.545$), **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.004$), T2–T0 ($p = 0.005$) and T3–T0 ($p = 0.002$) evaluations | **FAC**: no significant difference between the groups at T1–T0 ($p = 0.126$), T2–T0 ($p = 0.368$) and T3–T0 ($p = 0.342$) evaluations. **MI**: no significant difference between the groups at T1–T0 ($p = 0.107$), T2–T0 ($p = 0.385$) and T3–T0 ($p = 0.715$) evaluations. **AS**: no significant difference between the groups at T1–T0 ($p = 0.003$) and T2–T0 ($p = 0.016$) evaluations but not at the T3–T0 evaluation ($p = 0.405$). Significant difference in group 3 vs. group 1 results at T1–T0 ($p = 0.002$) and T2–T0 ($p = 0.013$) evaluations, as well as in group 3 vs. group 2 at T1–T0 ($p = 0.010$) and T2–T0 ($p = 0.015$) evaluations. No significant difference in group 2 vs. group 1 results. **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.512$), T2–T0 ($p = 0.416$), and T3–T0 ($p = 0.220$) evaluations |
| Picelli et al. (29) | **6MWT**: significant differences in walking distance between the groups at T1–T0 ($p = 0.014$) and T2–T0 ($p = 0.005$) evaluations. No significant difference between the groups at the T3–T0 evaluation ($p = 0.649$). Significant difference in group 3 vs. group 1 at T1–T0 ($p = 0.015$) and T2–T0 ($p = 0.001$) evaluations, as well as in group 3 vs. group 2 at T1–T0 ($p = 0.010$) and T2–T0 ($p = 0.015$) evaluations. No significant difference in group 2 vs. group 1 results. | **FAC**: no significant difference between the groups at T1–T0 ($p = 0.126$), T2–T0 ($p = 0.368$) and T3–T0 ($p = 0.342$) evaluations. **MI**: no significant difference between the groups at T1–T0 ($p = 0.107$), T2–T0 ($p = 0.385$) and T3–T0 ($p = 0.715$) evaluations. **AS**: no significant difference between the groups at T1–T0 ($p = 0.003$) and T2–T0 ($p = 0.016$) evaluations but not at the T3–T0 evaluation ($p = 0.405$). Significant difference in group 3 vs. group 1 results at T1–T0 ($p = 0.002$) and T2–T0 ($p = 0.013$) evaluations, as well as in group 3 vs. group 2 at T1–T0 ($p = 0.005$) and T2–T0 ($p = 0.016$) evaluations. No significant difference in group 2 vs. group 1 results. **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.512$), T2–T0 ($p = 0.416$), and T3–T0 ($p = 0.220$) evaluations | **FAC**: no significant difference between the groups at T1–T0 ($p = 0.126$), T2–T0 ($p = 0.368$) and T3–T0 ($p = 0.342$) evaluations. **MI**: no significant difference between the groups at T1–T0 ($p = 0.107$), T2–T0 ($p = 0.385$) and T3–T0 ($p = 0.715$) evaluations. **AS**: no significant difference between the groups at T1–T0 ($p = 0.003$) and T2–T0 ($p = 0.016$) evaluations but not at the T3–T0 evaluation ($p = 0.405$). Significant difference in group 3 vs. group 1 results at T1–T0 ($p = 0.002$) and T2–T0 ($p = 0.013$) evaluations, as well as in group 3 vs. group 2 at T1–T0 ($p = 0.005$) and T2–T0 ($p = 0.016$) evaluations. No significant difference in group 2 vs. group 1 results. **Ratio between single and double support duration**: no significant difference between the groups at T1–T0 ($p = 0.512$), T2–T0 ($p = 0.416$), and T3–T0 ($p = 0.220$) evaluations |
TABLE 5 | Continued

| Primary outcomes                                                                 | Secondary outcomes                                                                 |
|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Picelli et al. (31)                                                               | FAC: no significant difference between the groups at T1 (P = 0.565), T2 (P = 0.538) and T3 (P = 0.711) |
| 6MWT: no significant difference between the two groups at T1 (P = 0.976), T2 (P = 0.178) and T3 (P = 0.069). | MI: no significant difference between the groups at T1 (P = 0.854), T2 (P = 0.854) and T3 (P = 0.806) |
|                                                                                 | MAS: no significant difference between the groups at T1 (P = 0.720), T2 (P = 0.845) and T3 (P = 0.721) |
|                                                                                 | Cadence: no significant difference between the groups at T1 (P = 0.378), T2 (P = 0.635) and T3 (P = 0.778) |
| Seo et al. (30)                                                                   | Ratio between single and double support duration: no significant difference between the groups at T1 (P = 0.867), T2 (P = 0.715) and T3 (P = 0.666) |
| FAC: significant greater improvement in the Anodal group than in the Sham group at T2 (66.7% vs. 12.5%, p = 0.024) | |

6MWT: 6-min walking test; 10MWT, 10-meter walking test; AS, Ashworth scale; BBS, Berg balance scale; CL, contralesional; FAC, functional ambulations category; FIM, functional independence measure; FMA-LE, Fugl-Meyer assessment of lower extremity; IL, ipsilesional; JM, joint mobilization; LL, lower limb; MAS, modified Ashworth scale; MEP, motor-evoked potentials; MI leg subscore, motricity index leg subscore; MRC, medical research council scale; R-M, rivermead motricity index; SIS-16, stroke impact scale 16; ST, spatiotemporal; tDCS, transcranial direct current stimulation; tsDCS, transspinal direct current stimulation; TUG, timed up and go.

(MEP) of the affected and unaffected hemisphere to estimate interhemispheric balance inhibition. Table 5 shows the results of the studies.

**Methodological Quality**

Methodological quality was assessed with RoB-2 (26) for all the studies except one (28). As regards to the studies that compared real versus sham stimulation (18, 20, 28), the randomization process showed some concerns in one study (20) that did not report the random generation method. All the other biases were judged as “low risk.”

Differently, all the risks of bias of the methodological studies (29, 31, 32) were judged as “low risks.” Figures 2, 3 show the assessment of the risks of bias with the selected studies.

Naro et al. (28) study was evaluated using the MINORS individual score, and its final rating was 19 over 24. “The follow-up period appropriate to the aim of the study” and “loss to follow-up <5%” did not get a maximum score, while “prospective calculation of the study size” received the minimum score. Details of the MINORS score are reported in Table 6.

**DISCUSSION**

Restoring the ability to walk is the main aim of post-stroke rehabilitation; stroke survivors commonly present reduced ability to walk and limited activities inside and outside their home. Walking has been described to have a greater chance of post-stroke recovery than hand function because it is less dependent on the post-lesion integrity of the corticospinal tract. Although it requires a lower degree of residual motor function after stroke, gait performance often persists impaired in patients with chronic stroke due to decreased dorsiflexors strength and altered interaction between different connected functional networks involved in walking (31). The present systematic review investigated the effects of combining non-invasive brain stimulation with robot-assisted therapy for gait recovery in patients with chronic stroke.

It has been shown that NIBS techniques are able to harness brain plasticity (14), and there are several neurostimulation techniques and clinical applications, both open-loop and closed-loop, which seem to support cerebral neuroplasticity (34); the most studied and used are tDCS and TMS. While researchers have shown that tDCS has the potential to improve upper extremity motor recovery following stroke if paired with intensive motor training, only a few studies have examined the effects of tDCS on lower extremity motor function (20). This systematic review suggests that tDCS of the leg area of the motor cortex in the impaired hemisphere or cerebellar transcranial direct current stimulation (tcDCS) over the contralesional/ipsilesional cerebellar hemisphere combined or not with transcutaneous spinal direct current stimulation (tsDCS) and in addition to RAGT produce an improvement in walking function, in particular regarding walking ability, as measured by FAC, and walking capacity, as measured by 6MWT.

What can be for tDCS and RAGT the correct dosage, intensity, duration, order of application, and, moreover, for tDCS, type of stimulation and the site remains the subject of further studies.

There are few studies that use NIBS in association with RAGT. tDCS is among the NIBS elective technique of neurostimulation used in all clinical trials in combination with RAGT. Five out of seven studies, included in this review, used tDCS treatment protocol, which consisted in the stimulation of the motor cortex for 20 min, 5 days a week, for 2 weeks; despite this, it has not yet been determined the best stimulation site (i.e., affected or contralesional hemisphere) and the best timing of stimulation in patients with stroke (35, 36). Indeed, there was no difference
whether tDCS was administered before, during, or after the robotic therapy (28). This contrasts with the results found in a study combining tDCS with cognitive exercises that showed improvement in the execution times of the proposed exercises only when the tDCS was performed during training execution (37). Further studies are needed to clarify what is the right timing of stimulation during RAGT.

Furthermore, this systematic review highlighted the need to clarify whether the combination of different sites of tDCS and spinal stimulation can enhance the effects of RAGT; several studies suggest that the stimulation of the nervous system at multiple sites might result in a functional improvement in patients with stroke (e.g., paired associative stimulation—PAS of peripheral and central nervous system) (34). Because the central nervous system (CNS) controls both walking pattern generation and descending control from brain, methods aimed at promoting both spinal and supraspinal activities have been recommended in patients with stroke in order to retrain walking (38). It is plausible that combined supraspinal and spinal stimulation is needed to obtain significant additional effects on RAGT. Thoracic cathodal tDCS was found to improve motor unit recruitment in healthy people (39). Depending on the topography of spinal cells and the current direction, thoracic cathodal tDCS should make motoneurons more responsive to synaptic activation but less prone to generate spontaneous activity that inhibits interneuronal networks (39); this could produce positive spasticity control effects, but, furthermore, neurophysiological analyses are required to clarify the effects of tDCS on muscle overactivity (29) and to investigate both the specific timing in which it is applied and to clarify what the specific factors are that influence its effectiveness. (e.g., state of the brain and spontaneous neuronal activity) (34).

Future pieces of research will have to clarify the role of the combination of TMS with RAGT and the cerebellar implication in stroke recovery; the cerebellum is known to be strongly implicated in the functional reorganization of motor networks in patients with stroke, especially for gait and balance functions. Koch et al. (19) have demonstrated that cerebellar intermittent θ-burst stimulation promotes gait and balance recovery in patients with stroke by acting on cerebello-cortical plasticity. The patients were randomly assigned to treatment with CRB-iTBS or sham iTBS applied over the cerebellar hemisphere ipsilateral to the affected body side immediately before physiotherapy daily, during 3 weeks. The patients treated with CRB-iTBS, but not with sham iTBS, showed an improvement of gait and balance functions, as revealed by a pronounced increase in the mean...
TABLE 6 | Individual MINORS score.

| Criterion                                                                 | Naro et al. (28) |
|---------------------------------------------------------------------------|------------------|
| Clearly stated aim                                                        | 2                |
| Inclusion of consecutive patients                                         | 1                |
| Prospective collection of data                                            | 2                |
| Endpoints appropriate to the aim of the study                             | 2                |
| Unbiased assessment of the study endpoint                                 | 2                |
| Follow-up period appropriate to the aim of the study                      | 1                |
| Loss to follow up less than 5%                                            | 1                |
| Prospective calculation of the study size                                 | 0                |
| Additional criteria in the case of comparative study                      |                  |
| An adequate control group                                                 | 2                |
| Contemporary groups                                                       | 2                |
| Baseline equivalence of groups                                            | 2                |
| Adequate statistical analyses                                             | 2                |
| TOTAL SCORE                                                               | 19               |

0, not reported; 1, reported but inadequate; 2, reported and adequate.

(SE) Berg Balance Scale score. The patients treated with CRB-iTBS, but not sham iTBS, showed a reduction of step width at the gait analysis and an increase of neural activity over the posterior parietal cortex.

From Wessel et al. (40) in pieces of research, the cerebellum provides unique plasticity mechanisms and has vast connections to interact with neocortical areas. Moreover, the cerebellum could serve as a non-lesioned entry to the motor or cognitive system in supratentorial stroke.

Finally, papers in which a robotic treatment of the lower limb is associated with non-invasive brain stimulation have been few to date for a series of considerations that arise from literature and clinical experience: (1) not all rehabilitation centers have available exoskeletal robots and non-invasive brain stimulation techniques; (2) necessary personnel trained in the use of robots and NIBS; (3) the need for time, space, and human resources; (4) the need for broad and long-term patient compliance.

It would be important to compare more homogenous rehabilitation protocols to better appreciate their beneficial effects on post-stroke recovery. Moreover, considering that each stroke patient is unique in his/her characteristics, it would be probably better to design a therapeutic intervention tailored on every single patient (34).

Given the limited number of studies, the heterogeneity in the treatment protocol and the outcome assessment techniques, it was not possible to carry out a meta-analysis to obtain a quantitative summary of the results. We have found some limitations that may present challenges for future research: sample size and few RCT studies, no neurophysiological assessment with transcranial magnetic stimulation (TMS) was performed to assess cortical excitability and brain connectivity before and after treatments, the lesion site as cortical and subcortical has not been taken into account, sometimes, it was difficult to identify the precise injury extension (heterogeneous properties of stroke), finally, generalization of the stimulation protocols (30). Moreover, no short follow-up nor comparison was done with other non-invasive brain stimulation techniques, and the studies have included only patients with chronic supratentorial ischemic stroke, and we cannot draw conclusions about the effects of the current protocols of NIBS on RAGT in patients with other conditions, as acute or subacute supratentorial ischemic stroke, hemorrhagic, or cerebellar stroke.

The studies’ data support the hypothesis that anodal tDCS, combined with thoracic cathodal tsDCS, may be useful to improve the effects of RAGT in patients with chronic stroke. Moreover, cerebellum NIBS could represent a promising interventional strategy to improve residual motor functions and recovery after stroke, modulating cerebellar brain inhibition and facilitating motor skill relearning. Finally, no adverse events were recorded during the study (31).

CONCLUSION

The current systematic review showed a positive effect on walking recovery of combination of robot-assisted gait training with non-invasive brain stimulation. Specifically, the use of 20 min of tDCS (1.5–2 mA), 5 times/week for 2 weeks, can increase gait skills in patients with chronic stroke. Heterogeneity was found on the site of stimulation, the type of robot device (end effector, exoskeleton), and stimulation protocol with respect to robot-assisted therapy (before, online, or after). Future RCTs are needed to further validate the findings of these pieces of research.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

FB, MB, and GM: conceptualization. MB, FS, BC, LC, and AM: writing—original draft preparation. MB, LC, BC, and AM: methodology. BC, AM, GM, VD, FB, LZ, and SS: writing—review and editing. SS, VD, SP, LZ, and FB: supervision. All authors have read and agreed to the published version of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.795788/full#supplementary-material
REFERENCES

1. Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe: thirty-year projections of incidence, prevalence, death, and disability-adjusted life years. Stroke. (2020) 51:2418–27. doi: 10.1161/STROKEAHA.120.029606

2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. “Heart disease and stroke statistics—2020 update: a report from the American Heart Association,” in Circulation, London: Lippincott Williams and Wilkins (2020).

3. Pollock A, Baer G, Campbell P, Choo PL, Forster A, Morris J, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database Systemat Rev. (2014) 2014:CD001920. doi: 10.1002/14651858.CD001920.pub3

4. Ada L, Dean CM, Lindley R, Lloyd G. Improving Community Ambulation After Stroke: The AMBULATE Trial (2009).

5. Martino Cinnera A, Bonnì S, Pellicciari MC, Giorgi F, Caltagirone C, Koch G. Health-related quality of life (HRQoL) after stroke: Positive relationship between lower extremity and balance recovery. Topics Stroke Rehabil. (2020) 27:534–40. doi: 10.1080/10749357.2020.1726070

6. Ferrarello F, Baccini M, Rinaldi LA, Cavallini MC, Mossello E, Masotti G, et al. Efficacy of physiotherapy interventions late after stroke: a meta-analysis. J Neurol Neurosurg Psychiatry. (2011) 82:136–43. doi: 10.1136/jnnp.2009.196429

7. Veerbeek JM, Van Wegen E, Van Der Wees PJ, Claflin ES, Krishnan C, Khot SP. Emerging treatments for motor rehabilitation after stroke. Neurohospitalist. (2015) 5:77–88. doi: 10.14937/1941874414561023

8. Dias D, Laíns J, Pereira A, Nunes R, Caldas J, Amaral C, et al. Effects of transcranial direct current stimulation on upper and lower limb recovery of stroke patients with motor dysfunction: a meta-analysis. Neural Plast. (2019) 2019:2019:1372138. doi: 10.1038/s41398-019-01344

9. Teleda JS, Dixit S, Kumar G, Abobashir M. Robot-assisted gait training effect on function and gait speed in subacute and chronic stroke population: a systematic review and meta-analysis of randomized controlled trials. Clin Neurophysiol. (2019) 81:103–11. doi: 10.1159/000500747

10. Di Pino G, Pellegrino G, Assenza G, Capone F, Ferrari F, Formica D, et al. Modulation of brain plasticity in stroke: a novel model for neurorehabilitation. Nat Rev Neurol. (2014) 10:597–608. doi: 10.1038/nrneurol.2014.162

11. Bax I, Guo Z, Le H, Ren L, McClure MA, Mu Q. Different therapeutic effects of transcranial direct current stimulation on upper and lower limb recovery of stroke patients with motor dysfunction: a meta-analysis. Neuroplast. (2019) 2019:1372138. doi: 10.1155/2019/1372138

12. Marquez J, Van Vliet P, McElfuß P, Lagopoulos J, Parsons M. Transcranial direct current stimulation (tDCS): does it have merit in stroke rehabilitation? [[i]A systematic review. Int J Stroke. Offic J Int Stroke Soc. (2015) 10:306–16. doi: 10.1111/ijs.12169

13. Pinter MM, Brainin M. Role of repetitive transcranial magnetic stimulation in stroke rehabilitation. Front Neurol Neurosci. (2013) 32:112–21. doi: 10.3389/fneuro.2013.00364

14. Wang RY, Tseng HY, Liao KK, Wang CJ, Lai KL, Yang YR. RTMS combined with task-oriented training to improve symmetry of interhemispheric corticocortical excitability and gait performance after stroke: a randomized trial. Neurorehabil Neural Repair. (2012) 26:222–30. doi: 10.1177/1941010X11412365

15. Koch G, Bonni S, Casula EP, Iosa M, Paolucci S, Pellicciari MC, et al. Efficacy of cerebellar stimulation on gait and balance recovery in patients with hemiparetic stroke: a randomized clinical trial. JAMA Neurol. (2019) 76:170–8. doi: 10.1001/jamaneurol.2018.3639

16. Danzl MM, Chelette KC, Lee K, Lykins D, Sawaki L. Brain stimulation paired with novel locomotor training with robotic gait orthosis in chronic stroke: A feasibility study. NeuroRehabilit. (2013) 33:67–76. doi: 10.3233/NRE-130929

17. Alisharadah M, Al-Hussain F, Iqbal M, Hamza A, Yoo WK, Bashir S. The effect of transcranial direct current stimulation combined with functional task training on motor recovery in stroke patients. Eur Rev Med Pharmacol Sci. (2018) 22:785–92

18. Geroin C, Picelli A, Munari D, Waldner A, Tomelleri C, Smania N. Combined transcranial direct current stimulation and robot-assisted gait training in patients with chronic stroke: a preliminary comparison. Clin Rehabil. (2011) 25:537–48. doi: 10.1177/0269215510389497

19. Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 371:71. doi: 10.1136/bmj.n71

20. Mehtley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S, PICO, PICOs and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. Neuro. (2014) 14:579. doi: 10.1186/s12913-014-0579-0

21. Brown D. A Review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. (2020) 21:496–98. doi: 10.1177/1524839919893361

22. Sterne JAC, Savovíc J, Page MJ, Elbers RG, Blencowe N, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomized trials. The BMJ. (2019) 19:366. doi: 10.1136/bmj.34898

23. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. (2013) 73:572–6. doi: 10.1111/j.1445-2197.2003.02748.x

24. Naro A, Billeri L, Manuli A, Balletta T, Cannavo A, Portaro S, et al. Breaking the ice to improve motor outcomes in patients with chronic stroke: a retrospective clinical study on neuromodulation plus robotics. Neurologic Sci. (2020) 20:8. doi: 10.1007/s10072-020-04875-8

25. Picelli A, Chemello E, Castellazzi P, Roncari I, Waldner A, Saltuari L, et al. Combined effects of transcranial direct current stimulation (tDCS) and transcutaneous spinal direct current stimulation (tSDCS) on robot-assisted gait training in patients with chronic stroke: A pilot, double-blind, randomized controlled trial. Restor Neurol Neurosci. (2015) 33:357–68. doi: 10.3233/RNN-140474

26. Sea HG, Lee WH, Lee SH, Yi Y, Kim KD, Oh BM. Robotic-assisted gait training combined with transcranial direct current stimulation in chronic stroke patients: A pilot double-blind, randomized controlled trial. Restor Neurol Neurosci. (2017) 35:527–36. doi: 10.3233/RNN-170745

27. Picelli A, Brugnera A, Filippetti M, Mattuzi N, Chemello E, Modenesi A, et al. Effects of two different protocols of cerebellar transcranial direct current stimulation combined with transcutaneous spinal direct current stimulation on robot-assisted gait training in patients with chronic supratrochlear pain: A single blind, randomized controlled trial. Restor Neurol Neurosci. (2019) 37:97–107. doi: 10.3233/RNN-180895

28. Picelli A, Chemello E, Castellazzi P, Filippetti M, Brugnera A, Gandolfi M, et al. Combined effects of cerebellar transcranial direct current stimulation and transcutaneous spinal direct current stimulation on robot-assisted gait training in patients with chronic brain stroke: A pilot, single blind, randomized controlled trial. Restor Neurol Neurosci. (2018) 36:161–71. doi: 10.3233/RNN-170784

29. Herwig U, Satrapi P, Schönfeldt-Lecuona C. Using the International 10-20 EEG system for positioning of transcranial magnetic stimulation. Brain Topogr. (2003) 16:95–9. doi: 10.1023/B:BRAT.0000063333.93597.94
34. Ting WK, Fadul FA, Fecteau S, Ethier C. Neurostimulation for Stroke Rehabilitation. *Front Neurosci.* (2021) 15:649459. doi: 10.3389/fnins.2021.649459

35. Giacobbe V, Krebs HI, Volpe BT, Pascual-Leone A, Rykman A, Zesaiati G, et al. Transcranial direct current stimulation (tDCS) and robotic practice in chronic stroke: the dimension of timing. *NeuroRehabilitation.* (2013) 33:49–56. doi: 10.3233/NRE-130927

36. Powell ES, Carrico C, Westgate PM, Chelette KC, Nichols L, Reddy I, et al. Time configuration of combined neuromodulation and motor training after stroke: a proof-of-concept study. *NeuroRehabilitation.* (2016) 39:439–49. doi: 10.3233/NRE-161375

37. Oldrati V, Colombo B, Antonietti A. Combination of a short cognitive training and tDCS to enhance visuospatial skills: a comparison between online and offline neuromodulation. *Brain Res.* (2018) 1678:32–9. doi: 10.1016/j.brainres.2017.10.002

38. Yang JF, Gorassini M. Spinal and brain control of human walking: Implications for retraining of walking. *Neuroscientist.* (2006) 12:379–89. doi: 10.1177/1073858406292151

39. Bocci T, Vannini B, Torzini A, Mazzatenta A, Vergari M, Cogiamanian F, et al. Cathodal transcutaneous spinal direct current stimulation (tDCS) improves motor unit recruitment in healthy subjects. *Neuro. Sci. Lett.* (2014) 14:75–79. doi: 10.1016/j.neulet.2014.06.037

40. Wessel MJ, Hummel FC. Non-invasive cerebellar stimulation: a promising approach for stroke recovery? *Cerebellum.* (2018) 17:359–71. doi: 10.1007/s12311-017-0906-1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Bressi, Cinnera, Morone, Campagnola, Cricenti, Santacaterina, Miccinilli, Zollo, Paolucci, Di Lazzaro, Sterzi and Bravi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*